VEGFA and neoplasm: During an anti-angiogenic therapy against only one factor (i.e., VEGF-A), proangiogenic monocytes could mobilise other compensatory angiogenic factors to maintain angiogenic factors-driven inflammation and tumour growth supporting angiogenesis.